Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

Nature

Volumn 542, Issue 7642, 2017, Pages 483-493

  Compagno, Mara ^a   Wang, Qi ^a   Pighi, Chiara ^a   Cheong, Taek Chin ^a   Meng, Fei Long ^a,e   Poggio, Teresa ^b   Yeap, Leng Siew ^a,f   Karaca, Elif ^a   Blasco, Rafael B ^a   Langellotto, Fernanda ^a,g   Ambrogio, Chiara ^c   Voena, Claudia ^a,b   Wiestner, Adrian ^d   Kasar, Siddha N ^c   Brown, Jennifer R ^c   Sun, Jing ^c   Wu, Catherine J ^c   Gostissa, Monica ^a,g   Alt, Frederick W ^a   Chiarle, Roberto ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g Antigenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYLIDENE] 2,4 THIAZOLIDINEDIONE; ACTIVATION INDUCED CYTIDINE DEAMINASE; DUVELISIB; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN G1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); ANTINEOPLASTIC AGENT; CYTIDINE DEAMINASE; ENZYME INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; IPI-145; ISOQUINOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN; PIK3CD PROTEIN, MOUSE; PROTEIN TYROSINE KINASE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

CELLS AND CELL COMPONENTS; CHROMOSOME; ENZYME ACTIVITY; GENE EXPRESSION; GENOME; INHIBITION; MUTATION; ORGANIC NITROGEN COMPOUND; RECOMBINATION; TUMOR;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA CELL; MOUSE; MUTATION RATE; NONHUMAN; ONCOGENE C MYC; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RNA TRANSCRIPTION; SOMATIC HYPERMUTATION; TRANSCRIPTION INITIATION SITE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC RECOMBINATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYTIDINE DEAMINASE; ENZYME INHIBITORS; FEMALE; GENOMIC INSTABILITY; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN HEAVY CHAINS; ISOQUINOLINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES; RECOMBINATION, GENETIC; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TRANSLOCATION, GENETIC;

EID: 85016152789     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21406     Document Type: Article

References (43)

1. Alt, F. W., Zhang, Y., Meng, F. L., Guo, C. & Schwer, B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 152, 417-429 (2013)
2. Nussenzweig, A. & Nussenzweig, M. C. Origin of chromosomal translocations in lymphoid cancer. Cell 141, 27-38 (2010)
3. Robbiani, D. F. et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol. Cell 36, 631-641 (2009)
4. Omori, S. A. et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25, 545-557 (2006)
5. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013)
6. Gopal, A. K. et al. PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018 (2014)
7. Brown, J. R. et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110, for relapsed/refractory chronic lymphocytic leukemia. Blood 123, 3390-3397 (2014)
8. Dong, S. et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124, 3583-3586 (2014)
9. Chiarle, R. et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 147, 107-119 (2011)
10. Meng, F. L. et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 159, 1538-1548 (2014)
11. Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88-94 (2013)
12. Rush, J. S., Liu, M., Odegard, V. H., Unniraman, S. & Schatz, D. G. Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination. Proc. Natl Acad. Sci. USA 102, 13242-13247 (2005)
13. Angulo, I. et al. Phosphoinositide 3-kinase gene mutation predisposes to respiratory infection and airway damage. Science 342, 866-871 (2013)
14. Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110 result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88-97 (2014)
15. Klein, I. A. et al. Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 147, 95-106 (2011)
16. Hu, J., Tepsuporn, S., Meyers, R. M., Gostissa, M. & Alt, F. W. Developmental propagation of V(D)J recombination-associated DNA breaks and translocations in mature B cells via dicentric chromosomes. Proc. Natl Acad. Sci. USA 111, 10269-10274 (2014)
17. Yamane, A. et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat. Immunol. 12, 62-69 (2011)
18. Qian, J. et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 159, 1524-1537 (2014)
19. Yeap, L. S. et al. Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. Cell 163, 1124-1137 (2015)
20. Pavri, R. et al. Activation-induced cytidine deaminase targets DNA at sites of RNA polymerase II stalling by interaction with Spt5. Cell 143, 122-133 (2010)
21. Pefanis, E. et al. Noncoding RNA transcription targets AID to divergently transcribed loci in B cells. Nature 514, 389-393 (2014)
22. Potter, M. Neoplastic development in plasma cells. Immunol. Rev. 194, 177-195 (2003)
23. Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341-346 (2001)
24. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519-524 (2015)
25. Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525-530 (2015)
26. Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516 (2013)
27. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592-601 (2013)
28. Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine eaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015)
29. Palacios, F. et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 115, 4488-4496 (2010)
30. Klemm, L. et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 16, 232-245 (2009)
31. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000)
32. Cato, M. H., Yau, I. W. & Rickert, R. C. Magnetic-based purification of ntouched mouse germinal center B cells for ex vivo manipulation and biochemical analysis. Nat. Protocols 6, 953-960 (2011)
33. Kovalchuk, A. L., Müller, J. R. & Janz, S. Deletional remodeling of c-mycderegulating chromosomal translocations. Oncogene 15, 2369-2377 (1997)
34. Ramiro, A. R. et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118, 431-438 (2004)
35. Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863-864 (2011)
36. Zang, C. et al. A clustering approach for identification of enriched domains from histone modification ChIP-seq data. Bioinformatics 25, 1952-1958 (2009)
37. Camps, J. et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk. Res. 30, 923-934 (2006)
38. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009)
39. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011)
40. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012)
41. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010)
42. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)
43. Liu, M. et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 451, 841-845 (2008).